Publications

2024

Ondracek CR, Melanson SE, Doan L, Schulz KM, Kleinman S, Zhao Z, et al. Large-Scale Scientific Study Led by a Professional Organization during the COVID-19 Pandemic: Operations, Best Practices, and Lessons Learned. J Appl Lab Med. 2024;9(2):371-385.
Assaad MA, Michaud O, Semaan A, Sigouros M, Tranquille M, Phan A, et al. Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets. Mod Pathol. 2024;37(4):100452.
Zhang BX, Brantley KD, Rosenberg SM, Kirkner GJ, Collins LC, Ruddy KJ, et al. Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Res Treat. 2024;207(3):587-597.
Carbone A, Chadburn A, Gloghini A, Vaccher E, Bower M. Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management. Blood Rev. 2024;64:101167.
Francini E, Nuzzo PV, Fanelli GN. Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring. Cancers (Basel). 2024;16(3).
Papachristodoulou A, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplaca C, et al. Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. Eur Urol. 2024;85(4):361-372.
Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15:363.
Kinoshita H, Martinez-Ordoñez A, Cid-Diaz T, Han Q, Duran A, Muta Y, et al. Epithelial aPKC deficiency leads to stem cell loss preceding metaplasia in colorectal cancer initiation. Dev Cell. 2024;59(15):1972-1987.e8.
Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, et al. Canonical AREs are tumor suppressive regulatory elements in the prostate. bioRxiv. 2024.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700